Current Report Filing (8-k)
November 16 2021 - 08:54AM
Edgar (US Regulatory)
0001583771 false 0001583771 2021-11-16
2021-11-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of Report (Date of earliest event reported):
November 16, 2021
Hepion
Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
001-36856 |
|
46-2783806 |
| (State
or other jurisdiction |
|
(Commission |
|
IRS
Employer |
| of
incorporation or organization) |
|
File
Number) |
|
Identification No.) |
399 Thornall Street,
First Floor
Edison,
NJ
08837
(Address of principal executive offices)
Registrant’s telephone number, including area code: (732)
902-4000
(Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the
Act:
|
Title of each class: |
|
Trading Symbol(s) |
|
Name of each exchange on which registered: |
|
Common Stock |
|
HEPA |
|
Nasdaq Capital Market |
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
¨ Written communication pursuant to
Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
¨ Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
¨ Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth
company as defined in as defined in Rule 405 of the Securities
Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
x
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the
Exchange Act.
On November 16, 2021, Hepion
Pharmaceuticals, Inc. issued a press release announcing
results of a nonclinical research study showing that CRV431
significantly decreased the growth of liver tumors in a mouse model
of liver cancer. A copy of the press release is furnished as
Exhibit 99.1 to this Form 8-K.
|
Item 9.01 |
Financial Statements and
Exhibits |
(d) Exhibits
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
Dated: November 16, 2021
| |
HEPION PHARMACEUTICALS, INC. |
| |
|
| |
|
| |
By: |
/s/ Robert Foster |
| |
Robert Foster |
| |
Chief Executive Officer |
Hepion Pharmaceuticals (NASDAQ:HEPA)
Historical Stock Chart
From Apr 2022 to May 2022
Hepion Pharmaceuticals (NASDAQ:HEPA)
Historical Stock Chart
From May 2021 to May 2022
